Avosentan, formerly known as SPP301, R-639, and RO 67-0565, is an endothelin receptor antagonist. Avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. Avosentan is protective in hypertensive nephropathy at doses not causing fluid retention. Avosentan reduces albuminuria when added to standard treatment in people with type 2 diabetes and overt nephropathy but induces significant fluid overload and congestive heart failure. References: Baltatu OC, Zaugg CE, Schumacher C, Louie P, Campos LA, Bader M. Avosentan is protective in hypertensive nephropathy at doses not causing fluid retention. Pharmacol Res. 2014 Feb;80:9-13. doi: 10.1016/j.phrs.2013.12.003. Epub 2013 Dec 22. PubMed PMID: 24368192.

纯度：≥98%

CAS：290815-26-8